Clinical trials: EGFR Inhibitor-associated Rash
EGFRI Induced Acneiform Lesions
LUT014 for the Reduction of Dose-Limiting Acneiform Lesions Associated With EGFRI Treatment of mCRC
The study evaluates the efficacy and safety of two strengths of LUT014 Gel topically applied once a day for 4 weeks, compared to placebo, in metastatic colorectal cancer (mCRC) patients who developed Grade 2 or non-infected Grade…
- Trial name
- NCT04759664
- Testing
- LUT014 Gel (Dose 1), LUT014 Gel (Dose 2)
- Where
- 20 sites in United States, Israel
- Volunteers
- 117 people
- Sponsor
- Lutris Pharma Ltd.
EGFR Inhibitor-Induced Skin Rash
Prophylactic Treatment of Skin Rash Associated With EGFR Inhibitor Therapy
Epidermal growth factor receptor inhibitor (EGFRI) therapy for cancer is associated with potentially severe face and trunk skin acneiform rash.
- Trial name
- NCT04239846
- Testing
- AC-701 Topical Gel 0.3%
- Where
- 2 sites in Taiwan
- Volunteers
- 74 people
- Sponsor
- TWi Biotechnology, Inc.
Medication Reaction
Prevention of Drug Rash From Certain Cancer Therapies Using Tretinoin Cream
This research is being done to study whether using of topical tretinoin can help prevent the common rash that patients often get while taking epidermal growth factor inhibitor (EGFR-I) medications such ascetuximab or erlotinib.
- Trial name
- NCT01349556
- Testing
- Tretinoin
- Sponsor
- Johns Hopkins University
EGFR Inhibitor-associated Rash
TAR-0520 Gel in EGFR Inhibitor-induced Folliculitis
A Phase II, multicentric, randomized, double-blind, placebo-controlled, parallel- group trial to confirm the good safaty profile and to explore the preventive effect of topically applied TAR-0520 gel on folliculitis developed in…
- Trial name
- NCT06818058
- Testing
- Brimonidine tartrate Gel
- Where
- 3 sites in France
- Volunteers
- 60 people
- Sponsor
- Tarian Pharma
EGFR Inhibitor-associated Rash
A Study to Evaluate Topical ATR04-484 for EGFRi-Associated Dermal Toxicity
The goal of this randomized clinical trial is to learn if topical treatment with ATR04-484 can treat skin rash in patients undergoing EGFR inhibitor (EGFRi) therapy.
- Trial name
- NCT06830863
- Testing
- ATR04-484, Vehicle
- Where
- 6 sites in United States
- Volunteers
- 32 people
- Sponsor
- Azitra Inc.
EGFR Inhibitor-associated Rash
Safety, Tolerability and Systemic Absorption of Menadione Topical Lotion for Epidermal-Growth-Factor-Receptor (EGFR) Inhibitor-Associated Rash
This is a clinical research study of an experimental new medication, Menadione Topical Lotion (MTL). The study lotion is experimental and has not been approved for public use.
- Trial name
- NCT00656786
- Testing
- Menadione Topical Lotion
- Where
- 7 sites in United States, Canada
- Volunteers
- 18 people
- Sponsor
- Spectrum Pharmaceuticals, Inc
Acneiform Eruption Due to Chemical, Xerosis Cutis
Study to Investigate the Efficacy, Safety, and Tolerability of Topical HT-001 for the Treatment of Skin Toxicities Associated With Epidermal Growth Factor Receptor Inhibitors
The goal of this clinical trial is to learn about HT-001 Topical Gel for treatment of EGFR inhibitor-induced skin toxicities. The main questions it aims to answer are: Determine the therapeutic effect of HT-001 for treatment of…
- Conditions
- Acneiform Eruption Due to Chemical, Xerosis Cutis, Paronychia
- Trial name
- CLEER (NCT05639933)
- Testing
- HT-001 2% Topical Gel, HT-001 1% Topical Gel, HT-001 0.5% Topical Gel
- Where
- 12 sites in United States, Poland and 1 more
- Volunteers
- 152 people
- Sponsor
- Hoth Therapeutics, Inc.
Dermatologic Complications, Unspecified Adult Solid Tumor, Protocol Specific
Regenecare® Wound Gel in Treating Rash in Patients Receiving Cetuximab or Other Epidermal Growth Factor Receptor Inhibitor Therapy for Cancer
RATIONALE: Regenecare® wound gel may help relieve pain and itching in patients who develop an acne-like rash while undergoing treatment with cetuximab or another epidermal growth factor receptor inhibitor for cancer.
- Trial name
- NCT00498992
- Testing
- collagen/aloe vera/vitamin E/lidocaine topical hydrogel
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Ingalls Memorial Hospital